By Denny Jacob
Scientific instruments maker Bruker said it disagreed with a court ruling in a patent infringement case between its NanoString business and 10x Genomics.
Todd Garland, president of Bruker spatial biology division, said the company expects to promptly seek a stay of any injunction that is finally ordered in the case involving NanoString's GeoMx products.
"We also look forward to the appeal of our case being heard by the U.S. Court of Appeals for the Federal Circuit, a court that specializes in patent disputes," he added.
10x Genomics on Monday said the U.S. District Court for the District of Delaware ruled against the GeoMx products sold by Bruker.
The injunction, which the court said it will enter in January, is expected to prohibit Bruker from making, selling, using or offering to sell in the United States its GeoMx digital spatial profiler and associated instruments for RNA and protein detection, the company added. 10x Genomics also said the court affirmed the $31 million damages awarded by a jury in November 2023, as well as supplemented damages and interest that will be added to the total damages when the final judgment is entered.
The ruling follows the November 2023 jury verdict that found that NanoString's GeoMx products willfully infringed seven patents exclusively licensed to 10x Genomics by Prognosys.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
December 24, 2024 10:19 ET (15:19 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。